RxDoctor Payments Data

Sharon Lott

Adult Health · Paris, TXNPI 1730568338

Payments from drug & device makers

$2,359in general payments, 2019–2025

Across 84 payments — averaging $28.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$782
  • AbbVie$333
  • Idorsia Pharmaceuticals US Inc$285
  • Novo Nordisk$244
  • Lilly USA, LLC$222
  • Medtronic$125
  • plus $369 from 9 others

What the payments were for

  • Food & beverage$2,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,359 in reported general payments places this provider in the 75th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$5,420
Medicare patients
46
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$71,715
MounjaroTirzepatide20$21,979
Albuterol Sulfate HfaAlbuterol Sulfate26$1,025
Losartan Potassium35$682
Gabapentin30$659
Atorvastatin Calcium60$492
Buspirone Hcl21$472
Omeprazole38$424
Duloxetine Hcl18$365
Pregabalin16$349
Levothyroxine Sodium56$330
ClopidogrelClopidogrel Bisulfate28$322
Amlodipine Besylate55$258
Pantoprazole Sodium34$257
Potassium Chloride20$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$244$71,71565 claims
Lilly USA, LLCMounjaro$222$21,97920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 adult health providers in Texas.

Other adult health in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →